We can’t show the full text here under this license. Use the link below to read it at the source.
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
Which type 2 diabetes patients may benefit most from combined basal insulin and GLP-1 receptor agonist treatment?
AI simplified
Abstract
(FRCs) of basal insulin and GLP-1 receptor agonists may improve glycemic control in patients with type 2 diabetes.
- FRCs combine basal insulin and a GLP-1 receptor agonist in a single injection to reduce treatment burden.
- The target glycated haemoglobin (HbA1c) for most patients using FRCs is <7%, adjustable based on individual factors.
- An HbA1c goal of <6.5% may not be suitable for patients requiring basal insulin included in FRCs.
- Ideal candidates for FRCs include patients on oral medications with HbA1c <10% and those unable to manage multiple daily injections.
AI simplified
Key numbers
−1.6% to −2.9%
HbA1c Reduction from
Reduction in HbA1c after initiating FRC therapy.
−1.1% to −1.9%
HbA1c Reduction in Transitioning Patients
Reduction in HbA1c for patients switching to from basal insulin.